scholarly journals 0115 The Effect of Zolpidem on Sleep Dependent Emotional Memory Consolidation

SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A45-A46
Author(s):  
K C Simon ◽  
L Whitehurst ◽  
J Zhang ◽  
S Mednick
Keyword(s):  
Memory Consolidation ◽  
Verbal Memory ◽  
Significant Interaction ◽  
Emotional Memory ◽  
False Alarms ◽  
Double Blind Study ◽  
Drug Condition ◽  
Double Blind ◽  
Emotional Picture ◽  
Main Effect

Abstract Introduction Psychopharmacological treatment is widely promoted for insomnia treatment. Zolpidem (ZOL) is a GABA A agonist that depresses the central nervous that has demonstrated unexpected benefits, specifically increased sleep-dependent verbal memory via increased phase-amplitude coupling between slow oscillations and sleep spindles (Niknazar et al., 2015). Here we investigated if ZOL improved sleep-dependent emotional memory consolidation. Methods Using a within-subjects, cross-over design, we counterbalanced the administration of zolpidem (ZOL) or placebo (PBO) to 37 subjects in a double-blind study. Prior to drug or placebo administration, subjects rated their subjective physiological arousal of negative and neutral pictures. Subjects were tested on their recognition of the pictures twice, before (PM) and after (AM) a night of sleep. All subjects were monitored polysomnographically across the night. Results We analyzed emotional picture recognition using 2-by-2 ANOVA (emotion x drug condition). We found a main effect of emotional picture PM performance, such that negative pictures were remembered better than neutral pictures. There was a significant main effect of sleep on AM false alarm rate, with greater false alarms for negative than neutral pictures, a significant interaction between drug and emotion on AM dprime, and a significant interaction for the difference between AM and PM performance and drug condition. Specifically, we found memory maintenance for both emotional picture types in ZOL but negative picture memory decline in PBO. Across the night, ZOL showed greater memory performance than PBO if subjects had greater N2 SWA and N2 sigma activity (12-15Hz). Conclusion Zolpidem benefits sleep-dependent emotional memory consolidation by decreasing overnight forgetting. Further, it appears that spindle activity may play a key role in ZOL’s memory effect. Support NIH AG046646

scholarly journals 0099 The Effects of Sleep on the Consolidation of Fearful Memories

SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A39-A40
Author(s):  
M Arsic ◽  
L Heiss ◽  
A M Chambers
Keyword(s):  
Memory Consolidation ◽  
Emotional Memory ◽  
Neutral Condition ◽  
Emotion Induction ◽  
Induction Procedure ◽  
Main Effect ◽  
Before And After ◽  
Real World Learning ◽  
Emotional Events ◽  
The Impact

Abstract Introduction Previous research has found that emotionally intense stimuli are better remembered than neutral stimuli, especially after a period of sleep. However, few studies have examined memory for experienced emotional events, especially fearful ones. The purpose of the current study was to investigate the impact of sleep on memory consolidation using a fearful emotion induction task. Methods Thirty-three young adults (18.94±1.06 years; 64% female) were randomly assigned to either a fearful or neutral emotion induction condition. Participants were induced into their assigned emotion by visualizing each of eight emotion-congruent scenarios while corresponding music played in the background. Emotional state was measured using the Affect Grid before and after the emotion induction procedure. Twelve hours later, spanning either a day of wakefulness (wake group) or night of sleep (sleep group), participants were asked to recall the previously presented scenarios. Results A 2 x 2 ANOVA examined differences in the number of scenarios recalled between the conditions. A significant main effect of sleep was found, F(1,29)=8.41, p=.007, η 2p=.23, reflecting better recall in the sleep (3.21±1.78) vs. the wake group (1.79±1.72). There was also a main effect of emotion, F(1,29)=22.17, p<.001, η 2p=.43, reflecting better recall in the fear (3.58±1.54) vs. the neutral condition (1.29±1.44). However, there was no interaction. Results were similar for the number of details recalled between the conditions. The sleep group (12.74±9.09) recalled more details than the wake group (5.50±5.81), F(1,29)=8.05, p=.008, η 2p=.22. More details were also recalled in the fear condition (13.16±8.73) than the neutral condition (4.93±5.77), F(1,29)=10.54, p=.003, η 2p=.27. There was again no interaction. Conclusion Results demonstrate that both sleep and fearful emotion facilitate memory consolidation. This work both supports and extends existing research by examining emotional memory consolidation through the manipulation of experienced events, which may more closely approximate real world learning than previous methods. Support N/A

Effect of pomegranate fruit supplementation on performance and various markers in athletes and active subjects: a systematic review

2019 ◽  
pp. 1-15
Author(s):  
Alicja Urbaniak ◽  
Anna Skarpańska-Stejnborn
Keyword(s):  
Vessel Diameter ◽  
Whole Body ◽  
Double Blind Study ◽  
Double Blind ◽  
Physically Active ◽  
Highly Active ◽  
Body Strength ◽  
Rate Of Increase ◽  
Study Designs ◽  
Pomegranate Fruit

Abstract. The aim of the study was to review recent findings on the use of POM supplements in athletes of various disciplines and physically active participants. Eleven articles published between 2010 and 2018 were included, where the total number of investigated subjects was 176. Male participants constituted the majority of the group (n = 155), as compared to females (n = 21). 45% of research described was conducted on athletes, whereas the remaining studies were based on highly active participants. Randomised, crossover, double-blind study designs constituted the majority of the experimental designs used. POM supplementation varied in terms of form (pills/juice), dosage (50 ml–500 ml) and time of intervention (7 days–2 months) between studies. Among the reviewed articles, POM supplementation had an effect on the improvement of the following: whole body strength; feeling of vitality; acute and delayed muscle fatigue and soreness; increase in vessel diameter; blood flow and serum level of TAC; reduction in the rate of increase for HR, SBP, CK and LDH; support in the recovery of post-training CK, LDH, CRP and ASAT to their baseline levels; reduction of MMP2, MMP9, hsCRP and MDA; and increased activity of antioxidant enzymes (glutathione peroxidase and superoxide dismutase). In the majority of reviewed articles POM supplementation had a positive effect on a variety of parameters studied and the authors recommended it as a supplement for athletes and physically active bodies.

The Effects of a Caffeine Placebo and Experimenter Expectation on Blood Pressure, Heart Rate, Well-Being, and Cognitive Performance

2001 ◽  
Vol 6 (1) ◽  
pp. 15-25 ◽  
Author(s):  
Harald Walach ◽  
Stefan Schmidt ◽  
Yvonne-Michelle Bihr ◽  
Susanne Wiesch
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Cognitive Task ◽  
Well Being ◽  
Control Group ◽  
Double Blind ◽  
Main Effect ◽  
The Difference ◽  
Being There ◽  
To Receive

We studied the effect of experimenter expectations and different instructions in a balanced placebo design. 157 subjects were randomized into a 2 × 4 factorial design. Two experimenters were led to expect placebos either to produce physiological effects or not (pro- vs. antiplacebo). All subjects except a control group received a caffeine placebo. They were either made to expect coffee, no coffee, or were in a double-blind condition. Dependent measures were blood pressure, heart rate, well-being, and a cognitive task. There was one main effect on the instruction factor (p = 0.03) with the group “told no caffeine” reporting significantly better well-being. There was one main effect on the experimenter factor with subjects instructed by experimenter “proplacebo” having higher systolic blood pressure (p = 0.008). There was one interaction with subjects instructed by experimenter “proplacebo” to receive coffee doing worse in the cognitive task than the rest. Subjects instructed by experimenter “antiplacebo” were significantly less likely to believe the experimental instruction, and that mostly if they had been instructed to receive coffee. Contrary to the literature we could not show an effect of instruction, but there was an effect of experimenters. It is likely, however, that these experimenter effects were not due to experimental manipulations, but to the difference in personalities.

Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects

1987 ◽  
Vol 57 (03) ◽  
pp. 326-328 ◽  
Author(s):  
Ph Vague ◽  
I Juhan-Vague ◽  
M C Alessi ◽  
C Badier ◽  
J Valadier
Keyword(s):  
Plasminogen Activator ◽  
Fibrinolytic Activity ◽  
Plasma Insulin ◽  
Normal Glucose Tolerance ◽  
Double Blind Study ◽  
Obese Women ◽  
Double Blind ◽  
Normal Glucose ◽  
Plasma Insulin Levels ◽  
Obese Subjects

SummaryWe have previously observed a positive correlation between Plasminogen Activator Inhibition capacity (PA Inhibition), Body Mass Index (BMI) and plasma insulin levels in a population of non diabetic subjects. The anti diabetic biguanide Metformin which decreases insulin resistance has been reported to increase the blood fibrinolytic activity. Therefore we have studied the effect of Metformin on PA Inhibition levels in obese subjects with normal glucose tolerance. Eighteen obese women (O) (BMI: 31.4 ± 1.13, m ± S.E.M.) were compared to age matched controls (C) (BMI: 20.2 ± 0.8) and randomized to a 15 days treatment by Metformin (M) (1.7 g/day) or placebo (P) in a double blind study while on a weight maintaining diet. O compared to C had higher levels (m ± S.E.M.) of PA Inhibition (9 ± 1.8 IU/ml, versus 2.88 ± 0.29 p <0.01), lower euglobulin fibrinolytic activity (EFA) (4.95 ±1.17 mm versus 9 ± 0.29 p <0.05), higher plasma insulin (24.1 ±2.1. uU/ml), versus 12 ± 1 p <0.01) and triglyceride (1.32 ± 0.16 mmol/1, versus 0.8 ± 0.08 p <0.05). After 15 days of treatment, in group M a significant decrease in PA Inhibition (5.51 ± 1.4, versus 9.48 ±2.1 p <0.05) in plasma insulin (18.5 ±0.1, versus 24.5 ± 3.5, p <0.05) and plasma triglyceride (1.08 ± 0.1, versus 1.47 ± 0.3 p <0.05) and an increase in EFA (6.50 ± 0.28, versus 5.25 ± 0.35 p <0.05) were observed. No significant variation was observed in group P.

The Effect of Warfarin Sodium on the Duration of Platelet Aggregation

1967 ◽  
Vol 18 (03/04) ◽  
pp. 766-778 ◽  
Author(s):  
H. J Knieriem ◽  
A. B Chandler
Keyword(s):  
Platelet Count ◽  
Placebo Group ◽  
Platelet Aggregation ◽  
Prothrombin Time ◽  
Platelet Rich Plasma ◽  
Healthy Adults ◽  
Double Blind Study ◽  
Double Blind ◽  
Warfarin Sodium

SummaryThe effect of the administration of warfarin sodium (Coumadin®) on the duration of platelet aggregation in vitro was studied. Coumadin was given for 4 consecutive days to 10 healthy adults who were followed over a period of 9 days. The duration of adenosine diphosphate-induced platelet aggregation in platelet-rich plasma, the prothrombin time, and the platelet count of platelet-rich plasma were measured. Four other healthy adults received placebos and participated in a double-blind study with those receiving Coumadin.Although administration of Coumadin caused a prolongation of the prothrombin time to 2 or 21/2 times the normal value, a decrease in the duration of platelet aggregation was not observed. In most individuals who received Coumadin an increase in the duration of platelet aggregation occurred. The effect of Coumadin on platelet aggregation was not consistently related to the prothrombin time or to the platelet count. In the placebo group there was a distinct relation between the duration of platelet aggregation and the platelet count in platelet-rich plasma.The mean increase in the duration of platelet aggregation when compared to the control value before medication with Coumadin was 37.7%. In the placebo group there was a mean increase of 8.4%. The difference between the two groups is significant (p <0.001). Increased duration of platelet aggregation also occurred in two individuals who received Coumadin over a period of 10 and 16 days respectively.

Sign in / Sign up

Export Citation Format

Share Document